The biopharmaceutical company's novel compound has been accepted into a US government-funded program for evaluating potential treatments for methamphetamine and cocaine addiction.
The biopharmaceutical company has completed a corporate restructuring to streamline its operations and R&D framework across the UK, Ireland, and the US.
The biopharmaceutical company has appointed a highly experienced global leader to its board to support the next phase of strategic growth.
The clinical-stage biopharmaceutical firm reported widening losses but improved its cash position. It continues to advance its pipeline in addiction and mental health therapeutics, balancing progress with ongoing financial challenges.
The biopharmaceutical company has announced a heavily discounted equity raise, which is a negative sign indicating potential financial challenges.
The biopharmaceutical company's lead programmes for addiction and mental health disorders have been profiled in a media article.
The biopharmaceutical company reports positive pre-clinical results for its PTSD drug candidate, advancing three high-performing compounds to in vivo studies.
The biopharmaceutical company has initiated key translational studies to support the advancement of its esketamine oral thin film candidate SVN-002 towards a planned Phase 2b trial in the US for the treatment of Alcohol Use Disorder.
The specialty industrial machinery company has announced a heavily discounted equity raise, raising concerns about its financial health and future prospects.
The biopharmaceutical company's chairman will participate in a panel discussion at an exclusive investor event hosted by Lucid Capital Markets.